Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083234 | 0.91 | PDK1 (0.48) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL12658891 | 0.86 | LTB4R2 (0.68) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL10984675 | 0.83 | ALDH1A1 (0.47) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL7497334 | 0.83 | ALDH1A1 (0.61) | ALDH1A1GLAHTTSMN1; SMN2HPGD | |
| SCHEMBL11931984 | 0.82 | ATM (0.58) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL13741509 | 0.82 | ATM (0.58) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL11800781 | 0.81 | MLYCD (0.48) | ALDH1A1GLATSHR | |
| SCHEMBL12679663 | 0.81 | NPC1 (0.51) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL16297368 | 0.79 | NPC1 (0.57) | NPC1ALDH1A1GLAHTTRAB9A | |
| SCHEMBL12679677 | 0.78 | ATM (0.51) | NPC1ALDH1A1GLAHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061961-B1 | METHOD FOR DOUBLE STRAND SEQUENCING | OXFORD NANOPORE TECH PLC (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260072009-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20260072008-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | UNIV OXFORD INNOVATION LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20260063618-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | Oxford Nanopore Technolgies PLC (GB) | 2026-03-05 | — | — | US | disclosed |
| EP-4689159-A1 | METHOD AND KITS | Oxford Nanopore Technologies PLC (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-4270008-B1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | OXFORD NANOPORE TECH PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20260028379-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-12-30 | — | — | US | disclosed |
| EP-4127711-B1 | METHOD OF DETECTING AN ANALYTE IN A MEDIUM COMPRISING A LIGHT SCATTERING CONSTITUENT | KING S COLLEGE LONDON (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662489-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | Oxford University Innovation Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-20210363577-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2021-11-25 | — | — | US | disclosed |
| WO-2021111139-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
| EP-3802877-A1 | METHOD | Oxford Nanopore Technologies Limited (GB) | 2021-04-14 | — | — | EP | disclosed |
| CN-112189054-A | Method of producing a composite material | 牛津纳米孔科技公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20190352709-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES USING NANOPORES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2019-11-21 | — | — | US | disclosed |
| EP-3548636-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES USING NANOPORES | Oxford Nanopore Technologies Limited (GB) | 2019-10-09 | — | — | EP | disclosed |
| US-20190202876-A1 | MUTANT PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018100370-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES USING NANOPORES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2018-06-07 | — | — | WO | disclosed |
| US-20120010281-A1 | ANTIMICROBIAL AND ANTITUBERCULAR COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010281-A1 | ANTIMICROBIAL AND ANTITUBERCULAR COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072008-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | MAX, NPPA, NUP210 | NPC1 1656/4885ALDH1A1 4882/4885GLA 4661/4885 |
| US-12509721-B2 | Methods and systems for characterizing analytes using nanopores | DNA2, MTREX, DDX21 | NPC1 953/4885ALDH1A1 2568/4885GLA 4601/4885 |
| US-20260063618-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | NUP210, NPPA, NUP160 | NPC1 147/4885ALDH1A1 4884/4885GLA 4714/4885 |
| US-20260072009-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | NUP210, SLC9A2, SLC9A3 | NPC1 613/4885ALDH1A1 4883/4885GLA 4666/4885 |
| US-20260028379-A1 | MUTANT PORE | PTMS, NUP50, NUP205 | NPC1 448/4885ALDH1A1 4884/4885GLA 3540/4885 |
| US-20120010281-A1 | ANTIMICROBIAL AND ANTITUBERCULAR COMPOUNDS | TBK1, TBCD, TBKBP1 | NPC1 1385/4885ALDH1A1 3164/4885GLA 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.